Table of Contents Author Guidelines Submit a Manuscript
International Journal of Analytical Chemistry
Volume 2018, Article ID 1605950, 9 pages
https://doi.org/10.1155/2018/1605950
Research Article

LC-MS/MS Quantification of Tramadol and Gabapentin Utilizing Solid Phase Extraction

1Department of Pharmaceutical Analysis, Hindu College of Pharmacy, Guntur 522002, Andhra Pradesh, India
2College of Pharmaceutical Sciences, Acharya Nagarjuna University, Nagarjuna Nagar 522510, Guntur, Andhra Pradesh, India
3Clinical Pharmacology and Bio Sciences Division, RA Chem Pharma, Hyderabad, India
4College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA

Correspondence should be addressed to Pappula Nagaraju; moc.liamg@ujaraganaluppap

Received 11 March 2018; Revised 11 June 2018; Accepted 11 July 2018; Published 28 October 2018

Academic Editor: Barbara Bojko

Copyright © 2018 Pappula Nagaraju et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Kukanich and M. G. Papich, “Pharmacokinetics of tramadol and the metabolite O‐desmethyltramadol in dogs,” Journal of Veterinary Pharmacology and Therapeutics, vol. 27, pp. 239–246, 2004. View at Publisher · View at Google Scholar
  2. I. Yalein, F. Aksu, and C. Belzung, “Effects of desipramine and tramadol in a chronic mild stress model in mice are altered by yohimbine but not by pindolol,” European Journal of Pharmacology, vol. 514, pp. 165–174, 2005. View at Publisher · View at Google Scholar
  3. K. Miotto, A. K. Cho, M. A. Khalil, K. Blanco, J. D. Sasaki, and R. Rawson, “Trends in tramadol: pharmacology, metabolism, and misuse,” Anesthesia & Analgesia, vol. 124, no. 1, pp. 44–51, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. W. S. James and D. N. Young, “Tramadol,” Cmaj, vol. 185, no. 8, p. E352, 2013. View at Publisher · View at Google Scholar
  5. W. Leppert, “CYP2D6 in the metabolism of opioids for mild to moderate pain,” Pharmacology, vol. 87, no. 5-6, pp. 274–285, 2011. View at Publisher · View at Google Scholar
  6. L. Poulsen, L. Arendt-Nielsen, K. Brosen, and S. H. Sindrup, “The hypoalgesic effect of tramadol in relation to CYP2D6,” Clinical Pharmacology & Therapeutics, vol. 60, no. 6, pp. 636–644, 1996. View at Publisher · View at Google Scholar
  7. S. Groud and A. Sablotzki, “Clinical Pharmacology of Tramadol,” Clinical Pharmacokinetics, vol. 43, no. 13, pp. 879–923, 2004. View at Publisher · View at Google Scholar
  8. W. Lintz, H. Barth, R. Becker, E. Frankus, and E. Schmidt-Bothelt, “Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations-2nd communication: Drops with ethanol,” Arzneimittel-Forschung, vol. 48, no. 5, pp. 436–445, 1998. View at Google Scholar
  9. L. Qu, S. Feng, Y. Wu, and S. Da, “HPLC method for determination of tramadol hydrochloride in human plasma,” Journal of Sichuan University. Medical Science Edition = Sichuan Daxue Xuebao (Yixue Ban), vol. 34, no. 3, pp. 574-575, 2003. View at Google Scholar
  10. G. C. Yeh, M. T. Sheu, C. L. Yen, Y. W. Wang, C. H. Liu, and H. O. Ho, “High-performance liquid chromatographic method for determination of tramadol in human plasma,” Journal of Chromatography B: Biomedical Sciences and Applications, vol. 723, pp. 247–253, 1999. View at Publisher · View at Google Scholar
  11. S. H. Gan, R. Ismail, W. A. W. Adnan, and Z. Wan, “Method development and validation of a high-performance liquid chromatographic method for tramadol in human plasma using liquid–liquid extraction,” Journal of Chromatography B, vol. 772, pp. 123–129, 2002. View at Publisher · View at Google Scholar
  12. H. Ebrahimzadeh, Y. Yamini, A. Sedighi, and M. R. Rouini, “Determination of tramadol in human plasma and urine samples using liquid phase microextraction with back extraction combined with high performance liquid chromatography,” Journal of Chromatography B, vol. 863, no. 2, pp. 229–234, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Curticapean, D. Muntean, M. Curticapean, M. Dogaru, and C. Vari, “Optimized HPLC method for tramadol and O-desmethyl tramadol determination in human plasma,” Journal of Biochemical and Biophysical Methods, vol. 70, no. 6, pp. 1304–1312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. J. Bogusz, R.-D. Maier, K.-D. Krüger, and U. Kohls, “Determination of common drugs of abuse in body fluids using one isolation procedure and liquid chromatography-atmospheric-pressure chemical-ionization mass spectrometry,” Journal of Analytical Toxicology, vol. 22, no. 7, pp. 549–558, 1998. View at Publisher · View at Google Scholar
  15. A. Ceccato, F. Vanderbist, and B. Streel, “Enantiomeric determination of tramadol and its main metabolite O-desmethyltramadol in human plasma by liquid chromatography–tandem mass spectrometry,” Journal of Chromatography B: Biomedical Sciences and Applications, vol. 748, no. 1, pp. 65–76, 2000. View at Publisher · View at Google Scholar
  16. B. N. Patel, N. Sharma, M. Sanyal, and P. S. Shrivastav, “An accurate, rapid and sensitive determination of tramadol and its active metabolite O-desmethyltramadol in human plasma by LC–MS/MS,” Journal of Pharmaceutical and Biomedical Analysis, vol. 49, no. 2, pp. 354–366, 2009. View at Publisher · View at Google Scholar
  17. M. Gergov, P. Nokua, E. Vuori, and I. Ojanperä, “Simultaneous screening and quantification of 25 opioid drugs in post-mortem blood and urine by liquid chromatography-tandem mass spectrometry,” Forensic Science International, vol. 186, pp. 36–43, 2009. View at Google Scholar
  18. M. De Leo, M. Giorgi, G. Saccomanni, C. Manera, and A. Braca, “Evaluation of tramadol and its main metabolites in horse plasma by high-performance liquid chromatography/fluorescence and liquid chromatography/electrospray ionization tandem mass spectrometry techniques,” Rapid Communications in Mass Spectrometry, vol. 23, no. 2, pp. 228–236, 2009. View at Publisher · View at Google Scholar
  19. N. V. de Moraes, G. R. Lauretti, M. N. Napolitano et al., “Enantioselective analysis of unbound tramadol, O-desmethyltramadol and N-desmethyltramadol in plasma by ultrafiltration and LC–MS/MS: Application to clinical pharmacokinetics,” Journal of Chromatography B, vol. 880, pp. 140–147, 2012. View at Publisher · View at Google Scholar
  20. G. Saccomanni, S. Del Carlo, M. Giorgi, C. Manera, A. Saba, and M. Macchia, “Determination of tramadol and metabolites by HPLC-FL and HPLC-MS/MS in urine of dogs,” Journal of Pharmaceutical and Biomedical Analysis, vol. 53, pp. 194–199, 2010. View at Google Scholar
  21. L. Vlase, S. E. Leucuta, and S. Imre, “Determination of tramadol and O-desmethyltramadol in human plasma by high-performance liquid chromatography with mass spectrometry detection,” Talanta, vol. 75, no. 4, pp. 1104–1109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Hironari, N. Takafumi, M. Yasuaki, and J. Kawakami, “Validated determination method of tramadol and its desmethylates in human plasma using an isocratic LC-MS/MS and its clinical application to patients with cancer pain or non-cancer pain,” Journal of Pharmaceutical Health Care and Sciences, vol. 2, no. 25, pp. 1–9, 2016. View at Publisher · View at Google Scholar
  23. M. C. Walker and P. N. Patsalos, “Clinical pharmacokinetics of new antiepileptic drugs,” Pharmacology & Therapeutics, vol. 67, no. 3, pp. 351–384, 1995. View at Publisher · View at Google Scholar
  24. P. Gareri, T. Gravina, G. Ferreri, and G. De Sarro, “Treatment of epilepsy in the elderly Prog Neurobiol,” Journal of the Korean Medical Association, vol. 58, no. 5, pp. 389–407, 1999. View at Google Scholar
  25. R. K. Berlin, P. M. Butler, and M. D. Perloff, “Gabapentin therapy in psychiatric disorders: A systematic review,” Primary Care Companion to the Journal of Clinical Psychiatry, vol. 17, no. 5, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. M. J. McLean, “Gabapentin in the management of convulsive disorders,” Epilepsia, vol. 40, no. 6, pp. S39–S50, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. B. E. Gidal, L. L. Radulovic, S. Kruger, P. Rutecki, M. Pitterle, and H. N. Bockbrader, “Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability,” Epilepsy Research, vol. 40, no. 2-3, pp. 123–127, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Ouellet, H. N. Bockbrader, D. L. Wesche, D. Y. Shapiro, and E. Garofalo, “Population pharmacokinetics of gabapentin in infants and children,” Epilepsy Research, vol. 47, no. 3, pp. 229–241, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. C. W. Goodman and A. S. Brett, “Gabapentin and Pregabalin for Pain—Is Increased Prescribing a Cause for Concern?” The New England Journal of Medicine, vol. 377, pp. 411–414, 2017. View at Publisher · View at Google Scholar
  30. M. A. Rose and P. C. Kam, “Gabapentin: pharmacology and its use in pain management,” Anaesthesia, vol. 57, no. 5, Article ID 451462, pp. 451–462, 2002. View at Google Scholar
  31. C. Y. Chang, C. K. Challa, J. Shah, and J. D. Eloy, “Gabapentin in Acute Postoperative Pain Management,” BioMed Research International, vol. 2014, Article ID 631756, 7 pages, 2014. View at Publisher · View at Google Scholar
  32. J. Mao and L. L. Chen, “Gabapentin in Pain Management,” Anesthesia & Analgesia, vol. 91, pp. 680–687, 2000. View at Publisher · View at Google Scholar
  33. G. L. Lensmeyer, T. Kempf, B. Gidal, and D. Weibe, “Optimized method for determination of gabapentin in serum by HPLC,” Ther Drug Monit, vol. 17, pp. 251–258, 1995. View at Google Scholar
  34. Z. Zhu and L. Neirinck, “High-performance liquid chromatographic method for the determination of gabapentin in human plasma,” Journal of Chromatography B, vol. 779, pp. 307–312, 2002. View at Publisher · View at Google Scholar
  35. Q. Jiang and S. Li, “Rapid high-performance liquid chromatographic determination of serum gabapentin,” Journal of Chromatography B: Biomedical Sciences and Applications, vol. 727, no. 1-2, pp. 119–123, 1999. View at Publisher · View at Google Scholar
  36. D. C. Borrey, K. O. Godderis, D. R. Engelrelst Bernard, and M. R. Langlois, “Quantitative determination of vigabatrin and gabapentin in human serum by gas chromatography-mass spectrometry,” Clinica Chimica Acta, vol. 354, no. 1-2, pp. 147–151, 2005. View at Publisher · View at Google Scholar
  37. T. Wattananat and W. Akarawut, “Validated LC-MS-MS method for the determination of gabapentin in human plasma: Application to a bioequivalence study,” Journal of Chromatographic Science (JCS), vol. 47, no. 10, pp. 868–871, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. J.-H. Park, O.-H. Jhee, S.-H. Park et al., “Validated LC-MS/MS method for quantification of gabapentin in human plasma: application to pharmacokinetic and bioequivalence studies in Korean volunteers,” Biomedical Chromatography, vol. 21, no. 8, pp. 829–835, 2007. View at Publisher · View at Google Scholar
  39. N. V. S. Ramakrishna, K. N. Vishwottam, M. Koteshwara, S. Manoj, M. Santosh, and J. Chidambara, “Rapid quantification of gabapentin in human plasma by liquid chromatography/tandem mass spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, vol. 40, no. 2, pp. 360–368, 2006. View at Publisher · View at Google Scholar
  40. H. Y. Ji, D. W. Jeong, Y. H. Kim, H. H. Kim, Y. S. Yoon, and K. C. Lee, “Determination of gabapentin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry,” Rapid Communications in Mass Spectrometry, vol. 20, pp. 2127–2132, 2006. View at Publisher · View at Google Scholar
  41. Z. L. Xiong, J. Yu, J. F. He, F. Qin, and F. M. Li, “LC-MS/MS method for quantification and pharmacokinetic study of gabapentin in human plasma,” Yao Xue Xue Bao, vol. 46, no. 10, pp. 1246–1250, 2011. View at Google Scholar
  42. S. Muratović, K. Durić, E. Veljović et al., “Synthesis of biscoumarin derivatives as antimicrobial agents,” Asian Journal of Pharmaceutical and Clinical Research, vol. 6, no. 3, pp. 213–216, 2013. View at Google Scholar
  43. https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0014677/.
  44. Guidance for Industry: Bioanalytical method validation, U.S. Department of Health and Human services, Food and Drug administration, Rockville, MD, USA, 2001.
  45. Guidance for Industry: Bioanalytical method validation, European Medicines Agency, European Union, 2012.